Relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission

Where it is now

Done: IntroducedFebruary 25, 2025
Done: SubcommitteeMarch 3, 2025
Stopped: Senate committeeDied when the General Assembly ended
Next: Passes the Senate
Next: House committeeFunnel: by March 20, 2026
Next: Passes the House
Next: To the Governor
Next: Signed into law

Died when the session ended The 2026 session adjourned on May 3, 2026, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?

What’s in it

AI summary People on Iowa's Medicaid program will no longer need special permission from the state to get certain hepatitis C medicines if those drugs are already on the preferred list. Additionally, a state commission must look at the drug vosevi by July 2026 to decide if it should be added to that preferred list.¹

Read the official explanation

This bill relates to direct acting antivirals, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission (commission). The bill prohibits the department of health and human services from requiring prior authorization for direct acting antiviral medications used to treat hepatitis C that are on the preferred drug list for the medical assistance program. The bill requires the commission to review, by July 1, 2026, the prescription drug vosevi for placement on the preferred drug list pursuant to U.S.C. §1396r-8 as a preferred direct acting antiviral for treatment of hepatitis C.

Full bill text²

Senate subcommittee

Named March 3, 2025. It hasn’t reported yet.

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Lobbying

0 for · 0 against · 1 undecided · Who →